Suitable for a Wide Range of Cell Types
Cell types successfully transduced with BacMam reagents include numerous transformed cell lines (e.g. U2-OS, HEK 293, and HeLa). Beyond transformed cell lines BacMam transduction of many primary cells (e.g., fibroblasts, hepatocytes, cardiovascular cells and epithelial cells) and stem cells (e.g. neuronal and mesenchymal) have been shown to be highly efficient and generally without adverse affects, making this platform a very promising gene delivery platform technology. However, cells of hematopoietic origin show consistently poor transduction by BacMam technology, and are not recommended for use with the current technology. See Table 1 for a generalized comparison of the transduction efficiencies of BacMam 1.0 and BacMam 2.0 across different cell types. Gene expression can be increased by the use of an enhancer (HDAC inhibitor).
Table 1. Comparison of BacMam 1.0 and BacMam 2.0 across different cell types. Gene expression can be increased by using the BacMam Enhancer.
BacMam 1.0 No enhancer | BacMam 1.0 With enhancer | BacMam 2.0 No enhancer | BacMam 2.0 With enhancer | |
|---|---|---|---|---|
| Cell lines | +/– | ++ | ++ | ++ |
| Primary cells | + | ++ | ++ | ++ |
| Stem cells | – | ++ | ++ | ++ |
| Neurons | – | – | ++ | ++ |
| Immortalized T-cells | – | – | +/– | + |
| Primary T-cells and B-cells | – | – | – | – |
– = transduction efficiency <10% | ||||
Quick Links | |
| |
